

STATE OF KANSAS

DEPARTMENT OF HEALTH AND ENVIRONMENT
DIVISION OF HEALTH CARE FINANCE
LONDON STATE OFFICE BUILDING
900 SW JACKSON, SUITE 900 N
TOPEKA, KS 66612-1220



PHONE: (785) 296-3981
FAX: (785) 296-4813
WWW.KDHEKS.GOV

GOVERNOR JEFF COLYER, M.D.
JEFF ANDERSEN, ACTING SECRETARY

Preferred Drug List Committee Meeting Agenda, Open Session March 14, 2018 11:30am to 1pm

Meeting Location

DXC Technology (formerly HP Enterprise Services) Capital Room
6511 SE Forbes Ave., Bldg. 283 J, Topeka, Kansas 66619

Board Members

Taylor Gill, PharmD., BCPS
Wayne Wallace, M.D.
Raymond Magee, M.D.
Megan Hedden, PharmD.

Robert Haneke, PharmD
Emily Prohaska, PharmD., BCACP
Donna Sweet, M.D.

KDHE-DHCF Staff

Annette Grant, RPh.
Roxanne Chadwell, PharmD, CSP

Dr. Greg Lakin, Chief Medical Officer
Carol Arace, Administrative Assistant

DXC / HID Staff

Karen Kluczykowski, RPh.
Ellen McCaffrey, RN, BSN
Kathy Kaesewurm, RN, BSN

Taylor DeRuiter, PharmD.

I. Call to Order

A. Announcements

II. Old Business

A. Review and Approval of December 13, 2017 Meeting Minutes

B. Consent Agenda Items

i. PDL New Drug Placements

- | | |
|--------------------------|----------------------------|
| – Adzenys® ER Suspension | – Prozac Weekly® |
| – Protonix® Packets | – Apidra® |
| – Kenalog® 0.5% Ointment | – Apidra® Solostar® |
| – Lyrica® Solution | – Afrezza® |
| – Keppra® Solution | – Humalog® KwikPen® |
| – Seebri™ Neohaler® | – Humalog® Junior KwikPen® |
| – Khedezla® | – Bydureon® BCise™ |
| – Luvax CR® | |

III. New Business

- A. ADHD- Amphetamine Type - Class Review- New Agent: (Mydayis®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- B. ADHD- Methylphenidate Type- Class Review- New Agent: (Cotempla XR-ODT™)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- C. ADHD - Miscellaneous Type - New Class- (Clonidine IR, Guanfacine IR, Strattera®, Kapvay®, Intuniv®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- D. Anticholinergic for Maintenance of COPD- Class Review- New Agent: (Lonhala™ Magnair™)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- E. GLP-1 Receptor Agonists- Class Review- New Agent: (Ozempic®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- F. Corticosteroids -Intermediate Potency Topical – Class Review -New Agents: Valisone® (All strengths and dose forms).
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- G. Corticosteroids -High Potency Topical – Class Review – New Agents: Lidex®, Lidex E®
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- H. Immunomodulation Agents- Psoriatic Arthritis- Class Review, New Agents: (Taltz®, Xeljanz®, Xeljanz XR®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendation
- I. Insulin – Short-Acting and Intermediate-Acting- Class Review- New Agents: (Fiasp®, Fiasp® Flextouch®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- J. Intranasal Agents – Corticosteroids – Class Review – New Agent: (Xhance™)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- K. Ophthalmic – Prostaglandin Analog- Class Review- New Agent: (Vyzulta™)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations
- L. Opioids -Short Acting – Class Review- New Agent: (Codeine)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations

- M. Proton Pump Inhibitors- Class Review- New Agent: (Zegerid®)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations

- N. Class Name Change Request- Fluorouracil Agents to Actinic Keratosis Agents- New Agents: (Picato®, Solaraze® 3% Gel)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations

- O. Request to separate DPP-4 Inhibitor combination agents and DPP-4 Inhibitor single agents into two separate classes.
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations

- P. Request to separate SGLT2 Inhibitors into three separate classes –
 - New Class - SGLT2 Inhibitors, New Agent: (Steglatro™)
 - New Class - SGLT2 Inhibitor/DPP-4 Inhibitor, New Agent: (Steglujan™)
 - New Class - SGLT2 Inhibitors/Biguanide Combination, New Agent: (Segluromet™)
 - i. Public Comment*
 - ii. Committee Discussion/Recommendations

IV. Open Public Comment

V. Adjourn

****THIS AGENDA IS SUBJECT TO CHANGE****